News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cambridge-Based Regenerys Brings In Ex-GE Healthcare Exec For Top Post

3/28/2014 6:25:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

28 March 2014 -- Regenerys Ltd, (, the Sheffield- and Cambridge-based regenerative medicine company, has announced the appointment of Dr. Amr Abid as its new Chief Executive Officer.

Dr. Abid was formerly Head of Global Strategic Growth for the Life Sciences Division of GE Healthcare. He r eported to the President & CEO of Life Sciences, a $3.7B GE Business. Dr. Abid was a member of the Executive Management team, and led development of the strategy for growth and development of the Life Sciences at GE. Prior to that role, he was General Manager and Global leader for the Cell Technologies Division at GE Healthcare. Before his work with GE, Dr. Abid was Cell Systems Division Business Leader for the EMEA region at Life Technologies, formerly Invitrogen. He has a PhD in Pharmacology from Henri Poincare Nancy 1 University in France.

Dr. Abid commented “Regenerys is uniquely positioned to address the increasing needs of clinicians in field of regenerative medicine for reconstructive procedures. It is a real privilege to be invited to be Chief Executive of such a pioneering business, and to lead the future growth and development of Regenerys.”

Dr. Bill Mason, Chairman of Regenerys commented "We are delighted to welcome Dr. Abid to Regenerys as our new CEO. He brings a wealth of global leadership experience in the cell therapies and regenerative medicine fields to our Company. His input and insight going forward will be fundamental to the shape of our activities as we move ahead to develop our adipose and skin regenerative medicine businesses, and forge commercial partnerships worldwide."

About Regenerys

Regenerys Ltd ( is a regenerative medicine company offering medical logistics and services to facilitate better cosmetic outcomes in both breast cancer surgery and other cosmetic procedures. Regenerys enables storage and return of the patient's own adipose tissue for lipomodelling. Regenerys’ services are provided to both NHS and private healthcare providers. Regenerys also has novel and efficacious products for skin regeneration in the treatment of burns and potentially chronic wounds (Myskin, Cryoskin and Cryospray), using autologous and allogenic approaches with skin cells (keratinocytes).

The Regenerys adipose programme exists to serve the growing need for autologous adipose tissue banking, while avoiding the need for artificial prosthetics in reconstructive surgery. Adipose tissue has an increasing number of applications in the reconstructive and cosmetic surgical areas, as well as long term potential as a source of Adipose Derived Regenerative Cells (ADRCs) that may have therapeutic uses in wound healing, amongst others. An adipose tissue bank makes the use of this tissue practical and affordable for patient and healthcare provider alike. Regenerys has offices and HTA- and MHRA- licensed facilities in the Innovation Centre on the Sheffield University campus, and recently established itself at the St John’s Innovation Centre in Cambridge. The company has a strong Clinical Advisory Board.

Regenerys investors include New Wave Ventures from London and a group of East Anglian-based business angels.

For more information please contact:

Dr. Bill Mason
Tel: +44 7785 950134
Fax: +44 (0)1223 280264

Dr. Amr Abid
Tel: +44 7917 660817
Fax: +44 (0)1223 280264

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus